Lewis DF, Lake BG, Bird MG, Loizou GD, Dickins M, Goldfarb PS (Feb 2003). "Homology modelling of human CYP2E1 based on the CYP2C5 crystal structure: investigation of enzyme-substrate and enzyme-inhibitor interactions". Toxicology in Vitro. 17 (1): 93–105. doi:10.1016/s0887-2333(02)00098-x. PMID12537967.
Rendic S, Di Carlo FJ (1997). "Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors". Drug Metabolism Reviews. 29 (1–2): 413–580. doi:10.3109/03602539709037591. PMID9187528.
Bièche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P, de Waziers I (Sep 2007). "Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues". Pharmacogenetics and Genomics. 17 (9): 731–42. doi:10.1097/FPC.0b013e32810f2e58. PMID17700362. S2CID23317899.
Hayashi S, Watanabe J, Kawajiri K (Oct 1991). "Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene". Journal of Biochemistry. 110 (4): 559–65. doi:10.1093/oxfordjournals.jbchem.a123619. PMID1778977.
Westphal C, Konkel A, Schunck WH (Nov 2011). "CYP-eicosanoids--a new link between omega-3 fatty acids and cardiac disease?". Prostaglandins & Other Lipid Mediators. 96 (1–4): 99–108. doi:10.1016/j.prostaglandins.2011.09.001. PMID21945326.
Fleming I (Oct 2014). "The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease". Pharmacological Reviews. 66 (4): 1106–40. doi:10.1124/pr.113.007781. PMID25244930. S2CID39465144.
Fukuda T, Imai Y, Komori M, Nakamura M, Kusunose E, Satouchi K, Kusunose M (Jan 1993). "Replacement of Thr-303 of P450 2E1 with serine modifies the regioselectivity of its fatty acid hydroxylase activity". Journal of Biochemistry. 113 (1): 7–12. doi:10.1093/oxfordjournals.jbchem.a124006. PMID8454577.
Fukuda T, Imai Y, Komori M, Nakamura M, Kusunose E, Satouchi K, Kusunose M (Feb 1994). "Different mechanisms of regioselection of fatty acid hydroxylation by laurate (omega-1)-hydroxylating P450s, P450 2C2 and P450 2E1". Journal of Biochemistry. 115 (2): 338–44. doi:10.1093/oxfordjournals.jbchem.a124339. PMID8206883.
Kölble K (Dec 1993). "Regional mapping of short tandem repeats on human chromosome 10: cytochrome P450 gene CYP2E, D10S196, D10S220, and D10S225". Genomics. 18 (3): 702–4. doi:10.1016/S0888-7543(05)80378-7. PMID8307581.
Lieber CS (Jun 1999). "Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)--a review". Alcoholism: Clinical and Experimental Research. 23 (6): 991–1007. doi:10.1111/j.1530-0277.1999.tb04217.x. PMID10397283.
Johansson I, Ekström G, Scholte B, Puzycki D, Jörnvall H, Ingelman-Sundberg M (Mar 1988). "Ethanol-, fasting-, and acetone-inducible cytochromes P-450 in rat liver: regulation and characteristics of enzymes belonging to the IIB and IIE gene subfamilies". Biochemistry. 27 (6): 1925–34. doi:10.1021/bi00406a019. PMID3378038.
Lewis DF, Lake BG, Bird MG, Loizou GD, Dickins M, Goldfarb PS (Feb 2003). "Homology modelling of human CYP2E1 based on the CYP2C5 crystal structure: investigation of enzyme-substrate and enzyme-inhibitor interactions". Toxicology in Vitro. 17 (1): 93–105. doi:10.1016/s0887-2333(02)00098-x. PMID12537967.
Rendic S, Di Carlo FJ (1997). "Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors". Drug Metabolism Reviews. 29 (1–2): 413–580. doi:10.3109/03602539709037591. PMID9187528.
Bièche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P, de Waziers I (Sep 2007). "Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues". Pharmacogenetics and Genomics. 17 (9): 731–42. doi:10.1097/FPC.0b013e32810f2e58. PMID17700362. S2CID23317899.
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (Jul 1994). "Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians". The Journal of Pharmacology and Experimental Therapeutics. 270 (1): 414–23. PMID8035341.
Hayashi S, Watanabe J, Kawajiri K (Oct 1991). "Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene". Journal of Biochemistry. 110 (4): 559–65. doi:10.1093/oxfordjournals.jbchem.a123619. PMID1778977.
Westphal C, Konkel A, Schunck WH (Nov 2011). "CYP-eicosanoids--a new link between omega-3 fatty acids and cardiac disease?". Prostaglandins & Other Lipid Mediators. 96 (1–4): 99–108. doi:10.1016/j.prostaglandins.2011.09.001. PMID21945326.
Fleming I (Oct 2014). "The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease". Pharmacological Reviews. 66 (4): 1106–40. doi:10.1124/pr.113.007781. PMID25244930. S2CID39465144.
Fukuda T, Imai Y, Komori M, Nakamura M, Kusunose E, Satouchi K, Kusunose M (Jan 1993). "Replacement of Thr-303 of P450 2E1 with serine modifies the regioselectivity of its fatty acid hydroxylase activity". Journal of Biochemistry. 113 (1): 7–12. doi:10.1093/oxfordjournals.jbchem.a124006. PMID8454577.
Fukuda T, Imai Y, Komori M, Nakamura M, Kusunose E, Satouchi K, Kusunose M (Feb 1994). "Different mechanisms of regioselection of fatty acid hydroxylation by laurate (omega-1)-hydroxylating P450s, P450 2C2 and P450 2E1". Journal of Biochemistry. 115 (2): 338–44. doi:10.1093/oxfordjournals.jbchem.a124339. PMID8206883.
Kölble K (Dec 1993). "Regional mapping of short tandem repeats on human chromosome 10: cytochrome P450 gene CYP2E, D10S196, D10S220, and D10S225". Genomics. 18 (3): 702–4. doi:10.1016/S0888-7543(05)80378-7. PMID8307581.
Raucy JL, Schultz ED, Wester MR, Arora S, Johnston DE, Omdahl JL, Carpenter SP (Dec 1997). "Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity". Drug Metabolism and Disposition. 25 (12): 1429–35. PMID9394034.
Lieber CS (Jun 1999). "Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)--a review". Alcoholism: Clinical and Experimental Research. 23 (6): 991–1007. doi:10.1111/j.1530-0277.1999.tb04217.x. PMID10397283.
Johansson I, Ekström G, Scholte B, Puzycki D, Jörnvall H, Ingelman-Sundberg M (Mar 1988). "Ethanol-, fasting-, and acetone-inducible cytochromes P-450 in rat liver: regulation and characteristics of enzymes belonging to the IIB and IIE gene subfamilies". Biochemistry. 27 (6): 1925–34. doi:10.1021/bi00406a019. PMID3378038.
Raucy JL, Lasker JM, Kraner JC, Salazar DE, Lieber CS, Corcoran GB (Mar 1991). "Induction of cytochrome P450IIE1 in the obese overfed rat". Molecular Pharmacology. 39 (3): 275–80. PMID2005876.
Bièche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P, de Waziers I (Sep 2007). "Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues". Pharmacogenetics and Genomics. 17 (9): 731–42. doi:10.1097/FPC.0b013e32810f2e58. PMID17700362. S2CID23317899.
Fleming I (Oct 2014). "The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease". Pharmacological Reviews. 66 (4): 1106–40. doi:10.1124/pr.113.007781. PMID25244930. S2CID39465144.
"Assessment of Zopiclone"(PDF). World Health Organization. Essential Medicines and Health Products. World Health Organization. 2006. p. 9 (Section 5. Pharmacokinetics). Archived(PDF) from the original on 27 September 2007. Retrieved 5 December 2015.
"Assessment of Zopiclone"(PDF). World Health Organization. Essential Medicines and Health Products. World Health Organization. 2006. p. 9 (Section 5. Pharmacokinetics). Archived(PDF) from the original on 27 September 2007. Retrieved 5 December 2015.